Healthcare / BiotechnologyTaipei Exchange
$8.55
-0.05 (-0.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $8.0M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$258M
P/E
50.3x
↑EV/EBITDA
14.8x
↑ROE
2.6%
↑Gross Margin
38.2%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.3%
FCF CAGR
-42.4%
FCF margin
4.5%
FCF / Net income
1.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $179.1M · net income $5.2M · FCF $8.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $179.1M | $179.1M | $115.8M | $148.0M | $158.0M |
| Net Income | $5.2M | $5.2M | $-17.7M | $-19.6M | $12.3M |
| EBITDA | $20.3M | $20.3M | $-804000.00 | $973000.00 | $34.4M |
| EPS | — | — | -0.59 | -0.65 | 0.41 |
| Gross Margin | 38.2% | 38.2% | 46.0% | 45.6% | 42.6% |
| Operating Margin | -3.0% | -3.0% | -17.7% | -0.7% | 2.3% |
| Net Margin | 2.9% | 2.9% | -15.3% | -13.2% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.59 | 0.75 | 1.00 |
| Current Ratio | 3.69 | 3.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.0M | $8.0M | $-14.0M | $12.6M | $41.9M |
| Returns | |||||
| ROE | 2.6% | 2.6% | -9.1% | -9.3% | 5.3% |
| Valuation | |||||
| P/E | 50.29 | 50.29 | — | — | 25.49 |
| EV/EBITDA | 14.77 | 14.77 | — | 364.05 | 10.47 |
| P/B | 1.33 | 1.33 | 1.52 | 1.53 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 54.7% | 54.7% | -21.8% | -6.3% | — |
| EPS Growth | — | — | 9.2% | -258.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.59 → n/d
Residual
-16.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.